Clinical trials: completed, sponsored by SWOG Cancer Research Network
Breast Cancer
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer.
- Trial name
- NCT00127205
- Testing
- clodronate disodium, ibandronate sodium, zoledronic acid
- Volunteers
- 6,097 people
- Sponsor
- SWOG Cancer Research Network
ATM Gene Mutation, ATR Gene Mutation
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation
- Trial name
- NCT03377556
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 1,157 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- SWOG Cancer Research Network
CCND1 Gene Amplification, CCND2 Gene Amplification
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification
- Trial name
- NCT02785939
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Palbociclib
- Where
- 1,065 sites in United States
- Volunteers
- 53 people
- Sponsor
- SWOG Cancer Research Network
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02965378
- Testing
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Where
- 1,084 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen.
- Trial name
- NCT00075764
- Testing
- anastrozole, fulvestrant
- Where
- 426 sites in United States, Canada
- Volunteers
- 695 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread…
- Trial name
- NCT02164916
- Testing
- cetuximab, irinotecan hydrochloride, vemurafenib
- Where
- 763 sites in United States
- Volunteers
- 106 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
This phase II trial studies how well taselisib (GDC-0032) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Trial name
- NCT02785913
- Testing
- Laboratory Biomarker Analysis, Taselisib
- Where
- 1,111 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00436332
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 148 sites in United States
- Volunteers
- 84 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00792701
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 147 sites in United States
- Volunteers
- 85 people
- Sponsor
- SWOG Cancer Research Network
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00445848
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 153 sites in United States
- Volunteers
- 89 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Trial name
- NCT00661193
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel
- Where
- 124 sites in United States
- Volunteers
- 59 people
- Sponsor
- SWOG Cancer Research Network
Anxiety Disorder, Breast Cancer
S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors
RATIONALE: Physical activity, diet, and counseling may help breast and colorectal cancer survivors to lose weight and improve their quality of life.
- Conditions
- Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer
- Trial name
- NCT01453452
- Testing
- behavioral dietary intervention, exercise intervention, counseling intervention
- Where
- 58 sites in United States
- Volunteers
- 50 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00445601
- Testing
- gemcitabine hydrochloride
- Where
- 70 sites in United States
- Volunteers
- 406 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Infertility
S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: Goserelin blocks hormone production in the ovaries. It is not yet known whether ovarian suppression using goserelin will prevent ovarian failure (early menopause) in women receiving chemotherapy for breast cancer.
- Conditions
- Breast Cancer, Infertility, Menopausal Symptoms
- Trial name
- NCT00068601
- Testing
- cyclophosphamide, goserelin acetate
- Where
- 34 sites in Australia, Belgium and 4 more
- Volunteers
- 257 people
- Sponsor
- SWOG Cancer Research Network
Meningioma
S9005 Mifepristone in Meningioma
To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma.
- Trial name
- NCT03015701
- Testing
- Mifepristone
- Volunteers
- 193 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313
RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer.
- Trial name
- NCT00896727
- Testing
- gene expression analysis, protein expression analysis, fluorescent antibody technique
- Where
- United States
- Volunteers
- 2,100 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
- Trial name
- NCT01563861
- Testing
- RNA analysis, gene expression analysis, immunohistochemistry staining method
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer, Precancerous Condition
S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000
RATIONALE: Studying tissue samples in the laboratory from participants receiving treatment on the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SWOG-S0000 may help doctors predict a participant's response to treatment…
- Trial name
- ACP (NCT00706121)
- Testing
- Vitamin E, Selenium
- Where
- United States
- Volunteers
- 8,094 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network